Paul Song
Chief Scientific Officer Genequantum Healthcare
As CSO of GQ, I lead a multidisciplinary R&D organization spanning biology, antibody engineering, medicinal chemistry, translational sciences, toxicology, and PK/PD. I have helped shape the company’s scientific vision, R&D strategy, and portfolio, building a differentiated pipeline of next-generation ADCs targeting significant unmet medical needs. During my tenure, we have built a world-class ADC R&D organization and advanced multiple ADC programs into clinical and IND-stage development. Beyond R&D, I work closely with global pharma partners and investors on BD, strategic collaborations, fundraising, and corporate growth.
Seminars
- Addressing unmet therapeutic needs in gastric cancer through a novel dual payload ADC strategy
- Demonstrating promising anti-tumour activity across multiple patient-derived xenograft (PDX) models of gastric cancer
- Translating preclinical efficacy and emerging biomarker insights into indication selection and future clinical development